ArticleOncology letters2026
Prognostic and diagnostic significance of serum p53 antibody levels in patients with surgically treated pancreatic cancer.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serum p53 antibody (s-p53-Ab) levels increase in patients with various cancer types; however, their clinicopathological relevance in pancreatic ductal adenocarcinoma (PDAC) is not well defined. The present study aimed to assess the prognostic value of s-p53-Ab status in PDAC. The present retrospective study included 124 patients who underwent surgery for PDAC between January 2012 and December 2023. Patients were categorized into s-p53-Ab(+) and s-p53-Ab(-) groups using a cutoff value of 1.3 U/ml. Prognostic significance was examined using univariate and multivariate analyses. A total of 25 patients (20%) were s-p53-Ab-positive. The isolated s-p53-Ab positivity rates in stage I and II disease were 10 and 8%, respectively. The s-p53-Ab(+) group exhibited significantly worse overall survival (P=0.038) and relapse-free survival (P=0.037) than the s-p53-Ab(-) group. Multivariate analysis revealed that s-p53-Ab(+) independently predicted poorer relapse-free survival (P=0.044) and overall survival (P=0.048). s-p53-Ab was occasionally positive in stage I/II PDAC and was associated with more aggressive disease behavior. The present study was registered as a clinical trial in the University Hospital Medical Information Network Clinical Trials Registry (registration number, UMIN000014530; date of registration, 2011/07/11).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.